Index

Note: page numbers in italics refer to figures; those with suffix ‘n’ refer to notes

acculturation 63
ACPI gene 283
acquired capability for suicide (ACS) in eating disorders 125–127
adenyl cyclase-cAMP signaling system 344, 345, 348
adolescents 151–157
age at suicide 151
borderline personality disorder 111–112
bullying 166–171
depression treatment 155
developmental group therapy 155
epidemiology of suicide 151–152
ethnicity 151
family process treatments 155–156
fMRI in suicidal behavior 310
indigenous populations 159–160, 161
interventions 155–156
PKA changes in brain 348–349
psychiatric disorders 153–154
psychological factors 154
psychosocial factors 154–155
risk factors 152–155
sex 151
social process treatment 155–156
stain use disorders 118
suicidal ideation 152–153
suicide rate 79, 152
trends in 152, 153
venlafaxine and suicidal risk 240–241
see also youths/young adults
adrenergic receptors 327–328
adrenocorticotropic hormone (ACTH) 290
levels following early life adversity 290
adverse events
national rates 76–77
rare 76–77
African American males 63, 64
alpha1 adrenergic receptors 327–328
alpha2 adrenergic receptor(s) 328
gene polymorphisms 328
alpha3 adrenergic receptor antagonists 330
alternative psychopathology, epilepsy 132–133
gamma-aminobutyric acid (GABA) see GABA
ancient Egypt 3
ancient Greece 3, 4
ancient Rome 4
anorexia nervosa (AN) 123
fatal suicide attempts 124
low belongingness 126–127
non-fatal suicide attempts 124
postmortem studies 125
subtypes 123
suicidal ideation 123–124
anterior cingulate gyrus in borderline personality disorder 111
anticonvulsants
mood-stabilizing 222
see also antiepileptic drugs (AEDs)
antidepressants 74, 237–242
adverse effects 217–218
BDNF promoter effects 294
bipolar disorder 217–218
black warning 237–238, 363
changes following 77
unintended consequences 238, 239
bupropion 241
county-level analysis 77
cumulative sum method 75
ecological methods for rare adverse events 76–77
empirical Bayes screening 75
glial function targeting 332
locus coeruleus effects 332
meta-analysis of RCTs 77–80
mitrazapine 241
monoamine oxidase inhibitors 242
norepinephrine reuptake inhibitors (SSRIs); serotonin reuptake inhibitors (SNRIs)
antiepileptic drugs (AEDs) 130
suicide risk 133–134, 203
antipsychotic medication
atypical in norepinephrine signaling reduction 330–331
clozapine 229–234
extrapyramidal side effects 230
suicide rate 87, 222
antisocial personality disorder (APD) 112–113
anxiety 93–98
armed forces 191–194
bipolar disorder association 94
comorbid personality disorders 97
depression association 94
suicide risk 92
in epilepsy 132
aripiprazole 330
armed forces 191–198
anxiety 191–194
continuity of care 197
cultural factors 195
depression 191–194
epidemiology of suicide 191–193
help seeking 196–197
mental health care 197
surveillance 193
mental illness 194, 196
method of suicide 192
overseas deployment 195
post-traumatic stress disorder 191–194
suicidal ideation 238, 239
suicidality association 237
suicide rate 87
national 76–77
suicide risk 97, 240–241
children/adolescents 240–241
symptom control 97
tricyclic antidepressants 241–242
norepinephrine signaling manipulation 329
tyrosine hydroxylase expression reduction 326
see also selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs)

© in this web service Cambridge University Press
www.cambridge.org
army forces (cont.)
pre-enlistment suicidal history
192–193
prevention of suicide 195–196
protective factors 195
return from deployment 194
screening 193
social support 195
stress 194–195
suicidal ideation 191
suicide attempts 191
suicide rate 191, 192
suicide risk factors 193–195
surveillance 193
traumatic brain injury 194
treatment 196–197
unit cohesion 195
weapons management 197
astocytes 331–332
attachment theory 67
attachment-based family therapy
(ABFT) 156
atypical antipsychotics 331
audience reception studies of media
influence 378, 379
Bayes estimate of suicide rate 75, 78
belongingness 79
bereavement
Bowlby’s ideas 67–68
complicated grief 71
attachment-based family therapy
(based family therapy)
(controlled family therapy)
neurotransmitter 67
attachment theory 67
attachment-based family therapy
(ABFT) 156
attentional fixation 44
attachment theory 67
attachment-based family therapy
AFT) 156
attentional fixation 44
atypical antipsychotics 330–331
audience reception studies of media
influence 378, 379
Bayes estimate of suicide rate 75, 78
belongingness 79
bereavement
Bowlby’s ideas 67–68
complicated grief 71
coping strategy 70
definitions 66–67
framework 67–68
grief association 69–70
model 69
postvention 70–71
suicide-related 66–68
support strategies 70–71
beta-adrenergic receptors 328
between-subject designs 81
binge-eating disorder (BED) 123
fear of suicide attempts 124–125
non-fat suicide attempts 124
perceived burdensomeness 126
suicidal ideation 123–124
binge-eating/purging subtype anorexia
nervosa (BN) 123
bipolar disorder 62–63
antidepressant treatment
217–218
anxiety association 94
fMRI in suicidal behavior 310
follow-up care 363
index of lethality 219
lithium treatment 217–225
evidence for 218–219
patient monitoring 224
study limitations 224
suicide risk meta-analysis 219, 220
morbidity types 218
mortality 217
risk factors 95
screening for in depression 358
suicidality measure 283
suicide attempt 217
suicide rate 217
suicide risk 219
update of meta-analysis 220–221
treatment 217–225, 362–363
black box warning for antidepressants
237–238, 363
changes following 77
unintended consequences 238, 239
borderline personality disorder
(BPD) 110
adolescents 111–112
anterior cingulate gyrus volume
reduction 111
characteristic-associated suicide
110–111
comorbidities 110
lithium treatment 221
neurobiological underpinnings 111
non-suicidal self-injury
association 111
opioid deficit 111
structural brain alterations 309
fronto-parietal network in major
depressive disorder 308–309
fronto-striatal network in major
depressive disorder 307–309
fronto-parietal network in major
depressive disorder 308
fronto-striatal network in major
depressive disorder 307–309
fronto-parietal network in major
depressive disorder 308
fronto-striatal network in major
depressive disorder 307–309
fronto-parietal network in major
depressive disorder 308
fronto-striatal network in major
depressive disorder 307–309
fronto-parietal network in major
depressive disorder 308
fronto-striatal network in major
depressive disorder 307–309
fronto-parietal network in major
depressive disorder 308
fronto-striatal network in major
depressive disorder 307–309
fronto-parietal network in major
depressive disorder 308
fronto-striatal network in major
depressive disorder 307–309
fronto-parietal network in major
depressive disorder 308
fronto-striatal network in major
depressive disorder 307–309
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>celebrity suicides</td>
</tr>
<tr>
<td>suicide cluster effects 54, 56–57</td>
</tr>
<tr>
<td>suicide contagion effects 58</td>
</tr>
<tr>
<td>child abuse, physical/sexual 288</td>
</tr>
<tr>
<td>glucocorticoid receptor levels 340</td>
</tr>
<tr>
<td>children 151–157</td>
</tr>
<tr>
<td>age at suicide 151</td>
</tr>
<tr>
<td>bullying 166–171</td>
</tr>
<tr>
<td>depression treatment 155</td>
</tr>
<tr>
<td>developmental group therapy 155</td>
</tr>
<tr>
<td>early life adversity, burden 288–290</td>
</tr>
<tr>
<td>epidemiology of suicide 151–152</td>
</tr>
<tr>
<td>ethnicity 151</td>
</tr>
<tr>
<td>family process treatments 155–156</td>
</tr>
<tr>
<td>interventions 155–156</td>
</tr>
<tr>
<td>psychiatric disorders 153–154</td>
</tr>
<tr>
<td>psychological factors 154</td>
</tr>
<tr>
<td>psychosocial factors 154–155</td>
</tr>
<tr>
<td>risk factors 152–155</td>
</tr>
<tr>
<td>sex 151</td>
</tr>
<tr>
<td>social process treatment 155–156</td>
</tr>
<tr>
<td>suicidal behaviors 240–241, 241</td>
</tr>
<tr>
<td>suicidal ideation 152–153</td>
</tr>
<tr>
<td>suicide rate 79, 152</td>
</tr>
<tr>
<td>trends in 152, 153</td>
</tr>
<tr>
<td>venlafaxine and suicidal risk 240–241</td>
</tr>
<tr>
<td>see also youths/young adults</td>
</tr>
<tr>
<td>cholesterol levels 96</td>
</tr>
<tr>
<td>Christianity 3, 5</td>
</tr>
<tr>
<td>chromatin 289, 292</td>
</tr>
<tr>
<td>chronic obstructive pulmonary disease (COPD) 202</td>
</tr>
<tr>
<td>cigarette smoking 321–322, 323</td>
</tr>
<tr>
<td>clozapine 105–106, 229–234, 330</td>
</tr>
<tr>
<td>adverse effects 232–233</td>
</tr>
<tr>
<td>agranulocytosis monitoring 231, 232, 233</td>
</tr>
<tr>
<td>prevention of suicide 363</td>
</tr>
<tr>
<td>schizophrenia treatment 229</td>
</tr>
<tr>
<td>dosage 234</td>
</tr>
<tr>
<td>drug interactions 234</td>
</tr>
<tr>
<td>FDA approval 231–232</td>
</tr>
<tr>
<td>outcomes 233</td>
</tr>
<tr>
<td>smoking cessation 234</td>
</tr>
<tr>
<td>suicide risk 230–232</td>
</tr>
<tr>
<td>suicide risk reduction guidelines 233–234</td>
</tr>
<tr>
<td>underutilization 232–233</td>
</tr>
<tr>
<td>cognitive behavioral model of suicidality 309–310, 309</td>
</tr>
<tr>
<td>cognitive behavioral techniques 257–269</td>
</tr>
<tr>
<td>cognitive behavioral therapy (CBT) 363</td>
</tr>
<tr>
<td>general 268–269</td>
</tr>
<tr>
<td>integrated 156</td>
</tr>
<tr>
<td>psychosocial approaches to reduce suicidal behavior 257, 268–269, 271</td>
</tr>
<tr>
<td>schizophrenia 106</td>
</tr>
<tr>
<td>cognitive impairment, schizophrenia 103–104</td>
</tr>
<tr>
<td>cognitive model of suicidal behavior 256</td>
</tr>
<tr>
<td>cognitive rigidity 47</td>
</tr>
<tr>
<td>coherence 84</td>
</tr>
<tr>
<td>cohort studies 80</td>
</tr>
<tr>
<td>Collaborative Assessment and Management of Suicidality (CAMS) 367</td>
</tr>
<tr>
<td>college students 173–180</td>
</tr>
<tr>
<td>campus education/training 179</td>
</tr>
<tr>
<td>campus living 177–178</td>
</tr>
<tr>
<td>commuters 176</td>
</tr>
<tr>
<td>depression 175</td>
</tr>
<tr>
<td>epidemiology of suicide 173–174</td>
</tr>
<tr>
<td>gay, lesbian, bisexual, and transgender students 176–177</td>
</tr>
<tr>
<td>groups 175–177</td>
</tr>
<tr>
<td>impulsivity 177</td>
</tr>
<tr>
<td>international students 176</td>
</tr>
<tr>
<td>legal cases for institutional liability 178</td>
</tr>
<tr>
<td>life transition 174–175</td>
</tr>
<tr>
<td>means of suicide restriction 179</td>
</tr>
<tr>
<td>medical students 176</td>
</tr>
<tr>
<td>mental illness 173–174</td>
</tr>
<tr>
<td>older 176</td>
</tr>
<tr>
<td>prevention strategies 177–180</td>
</tr>
<tr>
<td>elements 179</td>
</tr>
<tr>
<td>programing 179–180</td>
</tr>
<tr>
<td>protective factors 177</td>
</tr>
<tr>
<td>reason for living 177</td>
</tr>
<tr>
<td>resources 175–177</td>
</tr>
<tr>
<td>screening for suicide risk 174, 179</td>
</tr>
<tr>
<td>social support 177</td>
</tr>
<tr>
<td>substance abuse 175</td>
</tr>
<tr>
<td>suicidal behaviors 173</td>
</tr>
<tr>
<td>suicide rate 173</td>
</tr>
<tr>
<td>suicide risk assessment 178, 179</td>
</tr>
<tr>
<td>suicide risk factors 174–177</td>
</tr>
<tr>
<td>command hallucinations 102</td>
</tr>
<tr>
<td>community-engaged approaches 258–259</td>
</tr>
<tr>
<td>indigenous populations 162–163</td>
</tr>
<tr>
<td>process for suicide prevention 163</td>
</tr>
<tr>
<td>comorbidity 259</td>
</tr>
<tr>
<td>older adults 185</td>
</tr>
<tr>
<td>schizophrenia with substance abuse 103</td>
</tr>
<tr>
<td>complicated grief treatment (CGT) 71, 71</td>
</tr>
<tr>
<td>confidentiality, risk assessment in emergency room 253</td>
</tr>
<tr>
<td>contact interventions 270–271</td>
</tr>
<tr>
<td>content analysis studies of media influence 378–379</td>
</tr>
<tr>
<td>coronary heart disease (CHD) 202</td>
</tr>
<tr>
<td>corpus callosum, major depressive disorder association 308–309</td>
</tr>
<tr>
<td>correctional facilities 208–215</td>
</tr>
<tr>
<td>causes of death 209</td>
</tr>
<tr>
<td>characteristics of suicides 209–212</td>
</tr>
<tr>
<td>conditions in 208–209</td>
</tr>
<tr>
<td>incarceration impact 210</td>
</tr>
<tr>
<td>interventions 212–215</td>
</tr>
<tr>
<td>mental health care requirements 209</td>
</tr>
<tr>
<td>method of suicide 210</td>
</tr>
<tr>
<td>multidisciplinary morbidity/mortality reviews 215</td>
</tr>
<tr>
<td>observation 214</td>
</tr>
<tr>
<td>physical environment 210, 214</td>
</tr>
<tr>
<td>population 210</td>
</tr>
<tr>
<td>precautions 212–215</td>
</tr>
<tr>
<td>privileges/property 214</td>
</tr>
<tr>
<td>psychosocial factors 210</td>
</tr>
<tr>
<td>risk factors 209–210</td>
</tr>
<tr>
<td>screening 213</td>
</tr>
<tr>
<td>single cell housing 210, 214</td>
</tr>
<tr>
<td>staff 214–215</td>
</tr>
<tr>
<td>stress of incarceration 210</td>
</tr>
<tr>
<td>suicide rates 209–212</td>
</tr>
<tr>
<td>suicide risk monitoring 213–214</td>
</tr>
<tr>
<td>profile 212–213</td>
</tr>
<tr>
<td>screening 213</td>
</tr>
<tr>
<td>corticoid receptors 340</td>
</tr>
<tr>
<td>corticotropin-releasing factor (CRF) 95, 290, 336–341</td>
</tr>
<tr>
<td>action on HPA axis 338</td>
</tr>
<tr>
<td>function 336, 340–341</td>
</tr>
<tr>
<td>levels 269, 271</td>
</tr>
<tr>
<td>in brain 341</td>
</tr>
<tr>
<td>in CNS 336</td>
</tr>
<tr>
<td>role in suicide 338–339</td>
</tr>
<tr>
<td>corticotropin-releasing factor binding site 339–340</td>
</tr>
<tr>
<td>HPA axis role 339–340</td>
</tr>
<tr>
<td>corticotropin-releasing factor (CRF) gene 293</td>
</tr>
<tr>
<td>corticotropin-releasing factor receptor 1 (CRF-R1) expression in brain 339</td>
</tr>
<tr>
<td>genetics 339</td>
</tr>
<tr>
<td>role in suicide 338–339</td>
</tr>
<tr>
<td>corticotropin-releasing factor receptor 2 (CRF-R2) expression in brain 339</td>
</tr>
<tr>
<td>role in suicide 338–339</td>
</tr>
<tr>
<td>cortisol 290 levels following early life adversity 290</td>
</tr>
<tr>
<td>CpG islands 289</td>
</tr>
<tr>
<td>CpG methylation 291</td>
</tr>
<tr>
<td>CREB signaling 349–350</td>
</tr>
<tr>
<td>criminal justice system see correctional facilities</td>
</tr>
<tr>
<td>crisis response plan 367</td>
</tr>
<tr>
<td>crisis safety planning 120</td>
</tr>
<tr>
<td>cultural factors 62–64</td>
</tr>
<tr>
<td>armed forces 195</td>
</tr>
<tr>
<td>children 151</td>
</tr>
<tr>
<td>indigenous populations 160, 161</td>
</tr>
<tr>
<td>mental illness 62–63</td>
</tr>
</tbody>
</table>
cultural factors (cont.)  
- predominant influence 63–64  
- youths 151  
- cultural-bound syndrome 62  
- cumulative sum (CUSUM) method 75  
- cyberbullying 169–170  

dementia  
- older adults 184–185  
- suicide risk 202–203  

depression  
- 62, 63, 93–98  
- alpha, adrenergic receptors 327–328  
- anxiety association 94  
- bipolar disorder screening 358  
- bullying association 167, 168  
- college students 175  
- comorbid personality disorders 97  
- epigenetic components in stress-induced animal models 298  
- fMRI 310–311  
- follow-up care 363  
- glia alterations 332  
- mortality 217  
- noradrenergic system  
- neurochemistry 326–328  
- norepinephrine  
- neurochemistry 326  
- role 332, 333  
- signaling manipulation 328–331  
- older adults 184, 188  
- panic attacks 97  
- physical illness 201–202  
- primary care detection/management 358  
- risk factors 94–95  
- schizophrenia 102  
- substance use disorders 119  
- suicide ideation 97  
- suicide risk in epilepsy 132  
- treatment 362–363  
- youths 155  
- tyrosine hydroxylase role 326–327  
- see also antidepressants; major depressive disorder (MDD)  
- depression-executive dysfunction syndrome 184  
- DerSimonian and Laird method 78  
- developmental group therapy (DGT) 155  
- diacylglycerol (DAG) 344  
- Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) 109–110, 114–115  
- dialectical behavioral therapy (DBT) 363  
- borderline personality disorder 112  
- psychosocial approaches to reduce suicidal behavior 268, 272  
- differential effects 83–84  

disability  
- older adults 185–187  
- schizophrenia 104  
- disinhibition 114  
- divalproex 222  
- DNA  
- chromatin 289  
- epigenetics 288–289  
- DNA methylation 289, 291  
- genome-wide alteration by early life stress 296–297  
- DMT1 expression 295  
- documentation, suicide risk assessment 253  
- domestic violence safety planning 370  
- dopaminergic system, substance use disorders 119  
- dorsal raphe nucleus 317  
- neuroanatomy 318–319, 319  
- serotonin indices alterations in depressed suicides 320  
- TPH2 levels 321  
- early life stress 322  
- drinking water, lithium in 221–222  
- dulosetine 241  
- early life, brain regulation 288–290  
- early life adversity  
- VAP gene 292–293  
- burden 288–290  
- cortisol levels 290  
- CRF gene 293  
- DNA methylation genome-wide alteration 296–297  
- HPA axis alterations 290–291  
- early life stress (ELS)  
- schizophrenia 103  
- TPH2 levels 321  
- eating disorder(s) 123–127  
- acquired capability for suicide 125–127  
- interpersonal theory of suicide 125–127  
- low belongingness 126–127  
- perceived burdensomeness 126  
- postmortem studies 125  
- psychological autopsy 125  
- social impairment 127  
- suicidal ideation 123–124  
- suicide attempts  
- fatal 124–125  
- non-fatal 124  
- non-fatal 124  
- eating disorder not otherwise specified (EDNOS) 123  
- fatal suicide attempts 125  
- ecological momentary assessment (EMA) 44  
- educational attainment, schizophrenia patients 104  
- emergency room 244–254  
- focus of care 247–250  

medical clearance and referral process 249–250  
- referral  
- to mental health specialists 249–250  
- to outpatient mental health treatment 366  
- screening  
- indicated 247  
- selective 247–248  
- universal 248  
- suicide risk assessment 247–249, 252–253, 253  
- capacity 252  
- collateral information 253  
- confidentiality 253  
- documentation 253  
- intoxication and capacity 252  
- involuntary treatment 252  
- standard of care 252  
- voluntary treatment 252  
- suicide risk identification 247–248  
- terminology 244–247  
- emotion regulation 68  
- empirical Bayes screening (EBS) 75, 78  
- Enlightenment 9–10  
- epidemiology of suicide 13–16, 93–94  
- adolescents 151–152  
- anxiety 93–98  
- armed forces 191–193  
- children 151–152  
- college students 173–174  
- depression 93–98  
- indigenous populations 159  
- pathophysiology 95–97  
- rates  
- by country 14–15  
- worldwide 64  
- USA 13  
- worldwide 13–14  
- rate 64  
- epigenetic modification 96  
- epigenetics 288–297  
- AVP gene 292–293  
- BDNF gene 293–294  
- components  
- in animal models of stress-induced depression 298  
- in suicide 297  
- CRF gene 293  
- definition 288–289  
- GABAergic system 295  
- genome-wide DNA methylation alteration by early life stress 296–297  
- GR gene 293–294  
- histone modifications 289  
- polyamines 296  
- serotonergic system 296  
- TrkB receptor gene 294–295
epilepsy 130–135
alternative psychopathology 132–133
completed suicide attempts 130
complex relationship with suicide 131–134
bidirectionality 131
epidemiology of suicide 130
GABA activity 131–132
HPA axis dysfunction 132
iatrogenic processes 132–133
identification of patients at risk of suicide 134–135
non-fatal suicide attempts 130
norepinephrine 131
pathogenic mechanisms 131–132
psychiatric risk factors 132
serotonergic system 131
suicidal ideation 130
suicide risk 132–134, 203
surgery and suicide risk 134
syndrome type 132
see also antiepileptic drugs (AEDs)
ERK1/2 MAP kinase signaling 352–353
excitopetrapom 239
ethnicity 62–64
children/young people 151
European history
Enlightenment 9–10
Middle Ages 6–7
nineteenth century 10–11
Renaissance 7–9
extrapyramidal side effects, antipsychotic medication 230
family history
schizophrenia 103
youths 154
family therapy 269–270
attachment-based 156
fictional suicide accounts 54
firearms 362
fluoxetine 238–239
Food and Drug Administration (FDA)
black box warning on antidepressants 237–238, 363
clozapine approval for schizophrenia treatment 231–232
forced normalization 132–133
fronto-striatal network, major depressive disorder association 307–309
functional magnetic resonance imaging (fMRI) 309–311
structural 307–309, 313
G protein 343, 344–346, 345
function 346
subunit classification 345–346
GABA, epilepsy 131–132
GABAergic system 295
GAD1 expression 295
gay, lesbian, bisexual, and transgender (GLBT) people 176–177
 genetic factors 95, 96
genome-wide association studies (GWAS) approaches to genetic associations 278–279
calcium channel genes 284
classical SNP-by-SNP 278–279, 283–284
errors 278
gene-wide 279
goals 277
pathway/network 279
suicidal behaviors 277–284
suicidality measures 279–283
technology 277
usage 277–278
glia 331–332
glutamatergic receptor (GR) 290–291, 336, 340
early life adversity in epigenetic regulation 291–292
glutamatergic receptor 1α (GR 1α) hippocampal expression 291
promoter methylation 291
glutamatergic receptor (GR) gene 291–292
glutamate 331
epiphanies 131–132
noradrenergic system role 331
glucocerebrosynthase kinase 3 (GSK3) signaling pathway 322
grief
Bowby’s ideas 67–68
complicated 67, 68–69
identification/treatment 71, 71
definitions 66–67
framework 67–68
integrated 66–67
model 69
mourning process 67
suicide bereavement 67–67
suicide-related 66–72
uniqueness of response 67, 68
guanine deaminase (GDA) gene 282
guanosine diphosphate (GDP) 344
guanosine triphosphate (GTP) 344
hallucinations, command 102
healing
model 69
process 68
Hebraism 3, 5
highly active antiretroviral therapy (HAART) 204
high-risk cognitive states 42–48
attentional fixation 44
cognitive rigidity 47
homicidal ideation 46–47
hopelessness 44–45
implicit associations 47
memory 47
perfectionism 46
problem solving deficits 45–46
research recommendations 47
suicide ideation 42–44
hippocampus
DNMT1 expression 295
GAD1 expression 295
glutamatergic receptor expression 291
GR 1α expression 291
NGF1-A levels 291
serotonin turnover 290
volume loss in early life adversity 290
historical trauma, indigenous populations 160–161
historian personality disorder (HPD) 112
HIV/AIDS
stigma 203
suicide risk 201–204
homicidal ideation 46–47
hopelessness 44–45
risk factor in schizophrenia 102
substance use disorders 118
hospitalization psychosocial approaches to reduce suicidal behavior 271
suicide risk 362
Huntington’s disease 202–203
5-hydroxyindoleacetic acid (5-HIAA) 96
levels in depressed suicides 321
in substance use disorders 119
suicide involvement 319–320
5-hydroxytryptamine (5-HT)
brain levels in psychological autopsy 317–322
brainstem levels 323
dorsal raphe nucleus alterations in depressed suicides 320
levels in depressed suicides 321
suicide involvement 319–320
synthesis 317
5-hydroxytryptamine 1A (5-HT1A) 320
5-hydroxytryptamine 2A (5-HT2A) 296
Index

5-hydroxytryptamine 2A (5-HT2A) receptor 312
5-hydroxytryptamine (5-HT) receptors 312
5-hydroxytryptamine transporter (5-HTT) 320
molecular neuroimaging 311–312, 311
hypothalamic–pituitary–adrenal (HPA) axis 336–341
alterations with early life adversity 290–291
animal models 290–291
CRF action on 338
CRF-BP role 339–340
dysfunction 95–96, 337–338
epilepsy 342
perinatal period 147
regulation 337, 337
stress effects 336
stress regulation 290
hypothalamus, paraventricular nucleus 292–293
imipramine, BDNF transcription 294
implicit associations 47
impulsivity 114–115
college students 177
substance use disorders 118
indigenous populations 159–164
familial factors 160, 161
epidemiology of suicide 159
historical trauma 160–161
interventions 161
community-engaged approaches 162–163
indigenous approaches 161–162
strengths-based approaches 161
prevention strategies 162
protective factors 160–161
researcher roles 162–163
suicide attempts 159
suicide risk factors 160–161
youths 159–160, 161
inflammatory markers, perinatal period 147
institutional liability, legal cases 178
integrated cognitive behavioral therapy (ICBT) 156
intent to act 27
suicide ideation 42
intent to die 19–21
interpersonal theory of suicide 256–257
eating disorders 125–127
interpersonal therapy (IPT) 269
intoxication, suicide risk assessment and capacity 252
intracellular signaling pathways 344
adenyl cyclase-CAMP 344
phosphoinositide 344
Islam 3, 5
ketamine 331
Latin America, epidemiology 14
legal issues, suicide risk assessment 252–253
lethal means restriction 361–362, 369
liability, legal cases 178
life neglect, environmental suicide risk factor 321–322
life stresses severe 89–90
see also early life stress (ELS); stress
lithium
bipolar disorder treatment 217–225
evidence for 218–219
patient monitoring 224
study limitations 224
suicide risk meta-analysis 219, 220
borderline personality disorder treatment 221
drinking water 221–222
mechanism of action 223
personality disorder treatment 221
prevention of suicide 363
psychopathological condition treatment 221
serotonergic system effects 223–224
locus coeruleus (LC) 325
alpha, adrenergic receptors 328
antidepressant actions 332–333
norepinephrine transporter 326–327
tyroline hydroxylase activity 326–327
logistic regression mixed-effects 78–79
person–time models 81–83
low serotonin syndrome 119
magnetic resonance imaging (MRI) see functional magnetic resonance imaging (fMRI)
major depressive disorder (MDD) fMRI 307–309, 311
5-HTT alterations 311, 311
treatment 362
Mantel-Haenszel (MH) method 78
MAP kinases 353
marginal structural models 84
maternal suicide 139–147
MeCP2 protein 292–293
media 378–381
audience reception studies 378, 379
content analysis studies 378–379
guidelines 380
influence studies 378–381
mitigation of effects 38
news production research 378, 379–380
newspaper reporting 53
quality and accuracy studies 378, 379
research studies 378
suicide cluster effects 53–54, 56–57
suicide contagion effects 53–54, 58, 380–381
suicide survivors 69–70
median raphe nucleus 317
anatomy 319
neuroanatomy 318, 319
medical claims data 80–84
case-control studies 80
memory 47
mental health care
armed forces 197
requirements in correctional facilities 209
surveillance in armed forces 193
mental health specialists referral to 249–250
medical clearance/process 249–250
suicide risk assessment/management 250–252
mental illness
armed forces 194, 196
college students 173–174
suicide prevention 174–176
older adults 184–185
perinatal period 139–141, 147
primary care detection/management 357–358
surveillance in armed forces 193
youths 153–154
metabolic syndrome, schizophrenia 104–105
method of suicide
armed forces 192
children 151–152, 153
suicide risk assessment/management 154
perinatal period 141
restriction of access to 361–362, 369
youths 151–152, 153
Mexicans/Mexican-Americans, epidemiology 14
Middle Ages 6–7
mineralocorticoid receptor (MR) 336, 340
mirtazapine 241, 330
molecular neuroimaging 311–312
monoamine oxidase(s) (MAO) 327
monoamine oxidase inhibitors (MAOIs) 242, 329
mood disorders
neuronal pathway plasticity alteration 343
primary care provider recognition/diagnosis 357–358
screening 358, 359, 360
see also named disorders
mourning 67
multiple sclerosis 203
myristoylated alanine-rich C kinase substrate (MARCKS) 347–348
Index

narcissistic personality disorder (NPD) 112
native populations see indigenous populations
nerve growth factor 1-a (NGF1-a) 290, 291
hippocampus levels 291
neuroimaging 307–314
MRI 309–311
structural 307–309, 313
modalities 307
molecular 311–312
neuronal pathways, plasticity alteration 343
neuroplasticity 96
neuroprotection 96
neuropsychological function 96
neurotransmitter receptors 343
news production research 378, 379
neurotransmitter receptors 343
neuroprotection 96
neuroplasticity 96

norepinephrine 325

no-harm, no-suicide contract 362
no-suicide contracts 367, 372
norepinephrine transporter 327, 330

obsessive-compulsive personality disorder (OCPD) 113

alpha2 adrenergic receptor actions 328
norepinephrine signaling
neurochemistry 326

schizophrenia treatment 232

older adults 182–189
comorbidity 185
dementia 184–185
depression 184, 188
disability 185–187
mental illness 184–185
physical illness 185–187, 204
prevention of suicide 183, 184, 187–185, 188
interventions 186
multi-level intervention 188–189
social connectedness 187–188
suicidal behaviors 182–183
suicidal ideation 182–183, 206
suicide rate 182, 183
opiod deficit in non-suicidal self-injury 111
osteoroporosis 202
outpatient referral 367
outreach interventions
contact 270–271
intensive 270
psychosocial approaches to reduce suicidal behavior 270–271
overseas deployment, armed forces 195

p75NTR signaling 351–352
panic disorder 94, 97
paraventricular nucleus (PVN) of hypothalamus 292–293
paroxetine 240

perfectionism 46

personality disorders 109–115

classification 109
Cluster A 113
Cluster B 110–113
Cluster C 113
lithium treatment 221
longitudinal studies 113–114
new models 109–110, 114–115
personality traits, emerging models 114–115
person–time logistic regression models 81–83
pharmaceutical drugs 74
access to for lethal overdose 362
between-subject designs 81
coherence 84
cohort studies 80
cumulative sum method 75
differential effects 83–84
drawings causal inferences from observational data 83–84
ecological methods for rare adverse events 76–77
empirical Bayes screening 75
history for psychological autopsy 318
marginal structural models 84
medical claims data 80–84
meta-analysis of RCTs 77–80

norepinephrine signaling
manipulation 328–331
novel statistical strategies 81–83
perinatal period 146
person–time logistic regression models 81–83
Poison method 75
post-marketing drug surveillance 80–84
propensity score matching 83
proratio reporting ratio 74–75
psychotherapy combination 363
psychotropic in perinatal period 146
spontaneous reports 74–76
SSRIs/SNRIs 75–76
suicidality in schizophrenia 105–106, 230
suicide rate 87
within-subject designs 81
see also named drugs and drug types
phosphoinositide (PI) signaling system 344, 345
phosphoinositide–specific phospholipase C (PI-PLC) 344, 347
physical illness 201–206
cancer 204–205
depression 201–202
HIV/AIDS 203–204
Huntington’s disease 202–203
life-threatening 201
multiple sclerosis 203
obesity 204
older adults 185–187, 204
screening 205–206
suicide risk factors 201–202
traumatic spinal cord/brain injuries 203
see also epilepsy
Poison method 75
polyamines 296
positron emission tomography (PET) 311–312
post-marketing drug surveillance 80–84
postpartum depression 139
postpartum period 139–147
age at suicidal behavior 144
breastfeeding 144–145
completed suicide attempts 140
epidemiology of mental illness 139–141
gonadal steroid role in mental illness 147
HPA axis changes 147
inflammatory markers 147
interpersonal relationships 144
marital status 144
psychiatric history 143–144
screening for suicide risk 145–146
serotonergic system 147
social support 144
Index

postpartum period (cont.)

suicidal ideation 139–140

suicide behaviors 141

suicide methods 141

suicide risk 139–141

suicide risk factors 143–145

Toxoplasma gondii infection 144

post-traumatic stress disorder (PTSD) 63

armed forces 191–194

rat model 294

prefrontal cortex, major depressive disorder association 308

pregnancy 139–147

age at suicidal behavior 144

completed suicide attempts 140

epidemiology of mental illness 139–141

gonadal steroid role in mental illness 147

HPA axis changes 147

inflammatory markers 147

interpersonal relationships 144

marital status 144

prevention of suicide 145–146

psychiatric history 143–144

screening for suicide risk 145–146

serotonergic system 147

social support 144

suicidal ideation 139–140

suicide behaviors 141

suicide methods 141

suicide risk 139–141

suicide risk factors 143–145

Toxoplasma gondii infection 144

unplanned 144

prevention of suicide 97

antidepressants 362–363

armed forces 195–196

bipolar disorder treatment 362–363

college students 177–180

community-engaged approaches 163

indigenous populations 162–163

definitions of types 247

depression treatment 362–363

indigenous populations 162

community-engaged approaches 162–163

lethal means restriction 361–362

mood disorder recognition/ diagnosis by primary care provider 357–358

older adults 183, 184, 187–185, 188

multi-level intervention 188–189

perinatal period 145–146

psychotherapy 363

public education 364

safety contract 362, 372–376

advantages 374–375

alternatives 375–376

history 372–373

reasons for avoiding 375

spread of 373

unintended consequences 373–374

safety planning for suicidal behavior 366–371

screening for suicidality 358

strategies to improve 357–364

substance use disorders 120

suicidal patient management 362

suicidality evaluation 358–361

suicide contagion 58

primary care

mood disorder recognition/diagnosis 357–358

psychiatric training 357

screening 205

suicidal ideation 35

interventions 205

problem orientation 45

problem solving deficits 45–46, 257

problem solving skills 45

instruments 45–46

problem solving therapy (PST) 257–268

pro-opiomelanocortin (POMC) 290

propensity score matching 83

proportional reporting ratio (P RR) 74–75

protein kinase A (PKA) 322, 344, 348–349

cAMP binding 348

subtypes 348, 349

protein kinase C (PKC) 344, 347–348

classes 347

isozyme expression 347

psychiatric diagnosis 93

suicide risk 18, 94

psychiatric disorders

youths 153–154

see also mental illness

psychiatric training, primary care 357

psychoanalytic therapy 270

psychological autopsy

brain serotonin levels 317–322

importance 317–318

neuropathological examination 318

pharmaceutical drug history 318

toxicological screen 318

see also tryptophan hydroxylase (TPH2)

psychopathological conditions

lithium treatment 221

suicide risk 357–358

psychosocial approaches to reduce suicidal behavior 256–273

adherence 273

cognitive behavioral techniques 257–269

cognitive behavioral therapy 257, 271

general 268–269

comparison conditions 272

dependent variables 272

dialectical behavioral therapy 268, 272

family therapy 269–270

generalizability 272

hospitalization 271

interpersonal therapy 269

outcomes targeted 257

outreach interventions 270–271

problem solving therapy 257–268

psychoanalytic therapy 270

randomized controlled trials 257–272

research studies 257

self-injury history 272–273

study duration 273

psychotherapy

borderline personality disorder 112

pharmacological drug combination 363

prevention of suicide 363

schizophrenia 106

psychotropic medication, perinatal period 146

public education, prevention of suicide 364

public health impact 17

quality and accuracy studies of media influence 378, 379

quetiapine 330

randomized controlled trials (RCTs)

cognitive behavioral therapy 257–269, 271

family therapy 269–270

hospitalization 271

interpersonal therapy 269

meta-analysis 77–80

outreach interventions 270–271

psychoanalytic therapy 270

psychosocial approaches to reduce suicidal behavior 257–272

research synthesis 79–80

suicidal thoughts/behaviors 258

rate multipliers 75

reason 3

reason for living, college students 177

receptor signaling 343–353

adenylyl cyclase-cAMP 344, 345

BDNF 350–351, 353

CREB 349–350

ERK1/2-MAP kinase 352–353

G proteins 344–346, 345

p53

phosphoinositide 344, 345

PI-PLC 347

PKA 348–349

PKC 347

TrkB 351, 353

Renaissance 7–9
Index

statistics (cont.)
Mantel-Haenszel method 78
marginal structural models 84
medical claims data 80–84
meta-analysis of RCTs 77–80
mixed-effects logistic regression
78–79
non-proportional hazards for suicide attempts 82
novel strategies 81–83
person–time logistic regression models 81–83
Poisson method 75
propensity score matching 83
proportional reporting ratio 74–75
rate multipliers 75
research synthesis 79–80
small area estimation 76
statistical properties comparison 79
suicide cluster techniques 52
within-subject designs 81
steroids, gonadal 147
stigma 69
armed forces 196–197
HIV/AIDS 203
strengths-based approaches for
indigenous populations 161
stress 95, 96
armed forces 194–195
early life stress
genome-wide DNA methylation
alteration 296–297
schizophrenia 103
HPA axis effects 336
incarceration in correctional facility 210
norepinephrine effects 326
role 333
regulation by HPA system 290
by polyamines 296
severe life stresses 89–90
see also early life adversity
stroke, suicide risk 202
substance abuse 62
college students 175
comorbid with schizophrenia 103
substance use disorders (SUDs) 117–120
adolescents 118
assessment 119–120
clinical characteristics 119
crisis safety planning 120
depression 119
dopaminergic system dysfunction 119
hopelessness 118
impulsivity 118
neurobiologic connections 118–119
prevention 120
serotonin system disorders 119
suicide prevalence 117
suicide risk 117–118
treatment 120
suicidal behavior
adolescents 240–241, 241
bullying 167–168
children 240–241, 241
college students 173
disclosure of intent 34
fMRI 310
genetics 277–278
genome-wide association studies 277–284
suicidality measure 282–283
homicidal ideation 46–47
older adults 182–183
prevention 366–371
psychosocial approaches to reduce
256–273
randomized controlled trials 258
range 19–21
suicidal ideation
association 42–43
distinction 21–27
suicidal crisis
response plan 367
dealing with 369
interventions 370
suicidal ideation
active 35
ambivalent state 43–44
antidepressants 238, 239
armed forces 191
behaviors 18–21
bullying 166, 167–168, 169
cancer 205
citalopram 239
construct 42
denial 34–35, 88–89
depressed patients 97
determining presence 34
eating disorders 123–124
ecological momentary assessment 44
emergency department 35
epilepsy 130
fluoxetine 239
fMRI 310–311
guide to better assessment 36–37
high-risk cognitive states 42–44
intent to act 27, 42
measures 43
older adults 44, 182–183, 206
passive 35
perinatal period 139–140
predictions 34–35
prevalence 34, 42
primary care 35
interventions 205
progression to attempt 247
randomized controlled trials 258
screening instruments 35, 43, 358
suicidal behavior
association 42–43
distinction 21–27
suicide cluster effects 54
suicide risk assessment 33–34, 43
treatment-emergent 279–282
young people 152–153
suicidal intent 244
suicidal patients, management 362
suicidal phenomena, definitions 19
suicidality
evaluation 358–361
screening 358
suicide
definition 67
see also method of suicide;
prevention of suicide
Suicide Assessment Follow-up
Engagement Treatment (SAFE VET) 370
suicide attempts
armed forces 191
bipolar disorder 217
bullying 166, 167–168
fatal
eating disorders 124–125
epilepsy 130
perinatal period 140
follow-up care 363–364
indigenous populations 159
methods in schizophrenia 103
non-fatal
eating disorders 124
epilepsy 130
non-proportional hazards 82
older adults 182–184
suicide clusters 52–55, 56–57
contextual effects 53
direct exposure to another’s suicide
55–56
fiction impact 54
geographical 52–53
media effects 53–54, 56–57
risk factors 52–53, 56–57
space-time 54–55
statistical techniques 52
suicide ideation media report effects 54
temporal 53–54
types 52–55
youths/young adults 55
suicide contagion 52, 55–56, 57–58
approach–avoidance conflict 57–58
mechanisms 57–58
media effects 53–54, 58, 380–381
mitigation 58
risk factors 57
Index

tryptophan hydroxylase (TPH2) (cont.)
  regulation 322
  serotonin dysregulation in brainstem 323
tryptophan hydroxylase (TPH)
  isoforms 321, 322
  tyrosine hydroxylase (TH) 326–327
understanding 3
  unit cohesion, armed forces 195
  USA, epidemiology 13
valproate 222
vasopressin (AVP) 290
  vasopressin (AVP) gene 292–293
  enhancer 292–293
venlafaxine 240–241
victimization
  bullying 168–169
  cyberbullying 169–170
  weapons management, armed forces 197
  within-subject designs 81
  youths/young adults 151–157
  age at suicide 151
  borderline personality disorder 111–112
  bullying 166–171
  changes following black box warning 77
  depression treatment 155
  developmental group therapy 155
epidemiology of suicide 151–152
  ethnicity 151
  family process treatments 155–156
  indigenous populations 159–160, 161
  interventions 155–156
  psychiatric disorders 153–154
  psychological factors 154
  psychosocial factors 154–155
  risk factors 152–155
  sex 151
  social process treatment 155–156
  suicidal ideation 152–153
  suicide clusters 55
  suicide rate 79, 152
  trends in 152, 153
see also college students